Ribosome specialization by cancer-associated ribosomal protein mutations: progress made and open questions

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Congenital mutations in ribosomal proteins (RPs) lead to Diamond-Blackfan anaemia (DBA), characterized by early-life hypo-proliferation.
• DBA patients exhibit an increased risk of developing cancer (hyper-proliferation) later in life.
• RP mutations are implicated in both benign and malignant conditions, highlighting a link between ribosome function and cell proliferation control.

Purpose of the Study:

• To elucidate the molecular mechanisms linking RP mutations to both hypo- and hyper-proliferation phenotypes.
• To explore the role of oxidative stress, DNA damage, and specialized ribosomes in cancer development associated with RP defects.
• To identify potential therapeutic strategies targeting RP mutations for cancer treatment.

Main Methods:

• Review and synthesis of existing literature on RP mutations, DBA, and cancer.
• Analysis of molecular pathways involving oxidative stress, DNA damage response, and oncogene translation.
• Discussion of the concept of 'onco-ribosome' specialization.

Main Results:

• RP mutations can induce a dual phenotype: hypo-proliferation in early life and hyper-proliferation (cancer) later.
• Key factors contributing to this transition include oxidative stress, DNA damage, and the hyper-translation of oncogenes by specialized ribosomes.
• Altered extra-ribosomal functions of RPs may also play a role in disease pathogenesis.

Conclusions:

• RP mutations present a complex relationship with cell proliferation, driving both deficiency and excess.
• The concept of 'onco-ribosomes' offers a framework for understanding how RP defects promote cancer.
• Further research into RP mutation-specific ribosome specialization is crucial for developing innovative cancer therapies.